Postprandial hyperglycaemia and vascular damage - The benefits of acarbose

Diabetes and Vascular Disease Research

Volumn 3, Issue 2, 2006, Pages 72-79

  Båvenholm, Peter N ^a,b   Efendic, Suad ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Medicine ^*  (Sweden)

Author keywords

Acarbose; Cardiovascular disease; Diabetes; Postprandial hyperglycaemia; Vascular damage

Indexed keywords

3 NITROTYROSINE; ACARBOSE; BIGUANIDE; GLITAZONE DERIVATIVE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MIGLITOL; OCTREOTIDE; PLACEBO; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VOGLIBOSE;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; META ANALYSIS; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SYSTEMATIC REVIEW;

ACARBOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; INFLAMMATION; OXIDATIVE STRESS; POSTPRANDIAL PERIOD; RISK FACTORS; VASCULAR DISEASES;

EID: 33750398030     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2006.017     Document Type: Review

References (83)

1. Bailes BK. Diabetes mellitus and its chronic complications. Aorn J 2002;76:266-76, 78-82;quiz 83-6.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
3. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
4. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.
5. Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S65-S67.
6. Harris R, Lux L, Bunton A et al. University of North Carolina Evidence-based Practice Center: Screening for type 2 diabetes mellitus, Systematic Evidence Review No. 19. Available at www.ahrq.gov/clinic/serfiles. htm; accessed February 2006.
7. Qiao Q, Tuomilehto J. Diagnostic criteria of glucose intolerance and mortality. Minerva Med 2001;92:113-19.
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
9. Diabetes Control and Complications Trial Research Group. The eftect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
10. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
11. Lawes CM, Parag V, Bennett DA et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004;27:2836-42.
12. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8.
13. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
14. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
16. Bischoff H. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995;18:303-11.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
18. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Letebvre PJ. Metabolic control may influence the increased superoxide generation in diabetic serum. Diabet Med 1991;8:540-2.
19. Du XL, Edelstein D, Rossetti L et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000;97:12222-6.
20. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90.
21. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001;108:635-6.
22. Ceriello A, Bortolotti N, Crescentini A et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 1998;28:329-33.
23. Ceriello A, Quagliaro L, Catone B et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002;25:1439-43.
24. Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.
25. Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72.
26. Ceriello A, Falleti E, Motz E et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998;30:146-9.
27. Marfella R, Esposito K, Giunta R et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2000;101:2247-51.
28. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
29. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992;231:25-30.
30. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999;22:(suppl 3):C10-C13.
31. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-28.
32. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991;88:2059-66.
33. Lechleitner M, Hoppichler F, Foger B, Patsch JR. Low-density lipoproteins of the postprandial state induce cellular cholesteryl ester accumulation in macrophages. Arterioscler Thromb 1994;14:1799-807.
34. Festa A, D'Agostino R Jr, Mykkanen L et al. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes Care 1999;22:1688-93.
35. McKeone BJ, Patsch JR, Pownall HJ. Plasma triglycerides determine low density lipoprotein composition, physical properties, and cell-specific binding in cultured cells. J Clin Invest 1993;91:1926-33.
36. Tribe RM, Poston L. Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction? Vasc Med 1996;1:195-206.
37. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999;144:229-35.
38. Temelkova-Kurktschiev T, Koehler C, Schaper F et al. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia 1998;41:706-12.
39. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-19.
40. Båvenholm P, De Faire U, Landou C et al. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Hearty 1998;19:402-10.
41. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR. Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 1999;222:178-84.
42. Ceriello A, Bortolotti N, Motz E et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999;48:1503-08.
43. Camejo G, Olsson U, Hurt-Camejo E, Baharamian N, Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl 2002;3:3-9.
44. Shurtz-Swirski R, Sela S, Herskovits AT et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 2001;24:104-10.
45. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon. J Clin Invest 1979;63:485-93.
46. Jones RL. Fibrinopeptide-A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes 1985;34:836-43.
47. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 1989;38:1162-3.
48. Ceriello A, Giacomello R, Stel G et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995;44:924-8.
49. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988;31:889-91.
50. Sakamoto T, Ogawa H, Kawano H et al. Rapid change of platelet aggregability in acute hyperglycemia. Detection by a novel laser-light scattering method. Thromb Haemost 2000;83:475-9.
51. Ceriello A, Taboga C, Tonutti L et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996;39:469-73.
52. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003;168:263-9.
53. Cipollone F, Iezzi A, Fazia M et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003;108:1070-7.
54. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
55. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4.
56. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36:689-92.
57. Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-7.
58. DECODE Study Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999;42:647-54.
59. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
60. de Vegt F, Dekker JM, Ruhe HG et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31.
61. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004;25:1990-7.
62. Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988;35:214-43.
63. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46:1025-54.
64. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999;57:19-29.
65. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000;59:521-49.
66. Matsuo T, Odaka H, Ikeda H. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 1992;55:314S-317S.
67. Meneilly GS, Ryan EA, Radziuk J et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23:1162-7.
68. Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998;106:231-3.
69. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002;28:195-200.
70. Hanefeld M, Haffner SM, Menschikowski M et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract 2002;55:221-7.
71. Chiasson JL, Josse RC, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
72. Wascher T, Schmolzer I, Stuehlinger M, Wiegratz A, Enderle M. Hyperglycemia-induced endothelial dysfunction in patients with impaired glucose tolerance is prevented by acarbose [Abstract 3020]. European Society of Cardiology Congress, 2004.
73. Rudofsky G, Reismann P, Schiekofer S et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 2004;36:630-8.
74. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
75. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose [ADA abstract 766]. Diabetes 2004;53 (suppl 2):A189.
76. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-8.
77. Handa N, Matsumoto M, Maeda H et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke 1990;21:1567-72.
78. Ludwig M, Kraft K, Rucker W, Huther AM. [Diagnosis of very early arteriosclerosis vascular changes using Duplex sonography.] Klin Wochenschr 1989;67:442-6.
79. Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia 2004;47:575-80.
80. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004;47:969-75;discussion 76-7.
81. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-16.
82. Van de Laar F, Lucassen P. No evidence for a reduction of myocardial infarctions by acarbose [letter]. Eur Heart J 2004;25:1179.
83. Hanefeld M. Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction - scientifically credible [letter]. Eur Heart J 2004;25:1179-80.